Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Thiogenesis Therapeutics Corp V.TTI

Alternate Symbol(s):  TTIPF

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing thiol-active therapeutic compounds, which are prodrugs used to treat unmet pediatric medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been... see more

TSXV:TTI - Post Discussion

View:
Post by Bassenon123 on Apr 13, 2022 4:43am

listing today

finally....live today...if all goes well
Comment by GoodAtCharts on Apr 19, 2022 12:31pm
I have some shares of this company any thoughts? Target prices?
Comment by Bassenon123 on Apr 20, 2022 4:13am
Waiting to hear the results of the PK study in Australia (dosage in 12 volunteers) which is expected to complete in H1 2022
Comment by GoodAtCharts on Apr 20, 2022 11:19am
Complete in H1 or Q1?
Comment by Bassenon123 on Apr 22, 2022 3:36am
H1..
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities